Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597167 | 0.98 | CYP2B6 (0.52) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL8013935 | 0.98 | CYP2B6 (0.52) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL8017738 | 0.96 | CYP2B6 (0.50) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL4541997 | 0.83 | KCNA5 (0.48) | OPRM1LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9816209 | 0.83 | CHRM2 (0.48) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| SCHEMBL9366900 | 0.81 | CYP2B6 (0.49) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL14354381 | 0.78 | CYP2B6 (0.39) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL2707429 | 0.78 | CYP2B6 (0.58) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL10587081 | 0.77 | CYP2B6 (0.45) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL9076530 | 0.77 | CHRM4 (0.63) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | claimed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | claimed |
| CN-113226313-A | Sustained release compositions comprising trihexyphenidyl | 卡希夫生物科学有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-111044663-A | Method for determining concentration of diphenhydrasol in blood plasma by liquid chromatography-mass spectrometry | 南京立顺康达医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3510092-A1 | PLASTIC COMPOSITION, PRODUCTION METHOD, AND USE OF SAME | ATP Aicher + Tröbs Produktentwicklung GmbH (DE) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018141587-A1 | PLASTIC COMPOSITION, PRODUCTION METHOD, AND USE OF SAME | ATP Aicher + Tröbs Produktentwicklung GmbH (DE) | 2018-08-09 | — | — | WO | disclosed |
| EP-0634932-B1 | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS | ALLERGAN INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-0634932-A1 | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS | ALLERGAN, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | CYP2B6 4744/4885CHRM2 3610/4885CHRM1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.